Enovix Corporation vs Tenet Healthcare Corporation — how do they compare? Enovix Corporation trades at $2.54 (market cap $561.79M), while Tenet Healthcare Corporation trades at $260 (market cap $20.92B). The key difference: Tenet Healthcare Corporation is far larger — about 37.2× Enovix Corporation's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Enovix Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Tenet Healthcare Corporation for 15 Days on average.
| ENVX | THC | |
|---|---|---|
Market Cap | $561.79M | $20.92B |
Volume | 5,898,906 | 455,764 |
Sector | Industrials | Health |
52-Week High | $13.19 | $280.77 |
52-Week Low | $2.50 | $161.37 |
Typical Hold Time | 11 Days | 15 Days |
Enterprise Value | $623.49M | $32.00B |
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.55, down 5.56% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with negative moving averages and oscillators. Fundamentally, the company continues to burn cash with a net income margin of -473.89% in 2026, though revenue growth remains positive at 32% year-over-year. Recent CEO transition and strategic focus on defense battery manufacturing create uncertainty about execution.
The outlook remains challenging with significant cash burn and negative profitability, though analyst consensus is bullish with a $10.75 price target representing 321% upside. Key risks include execution challenges, high cash consumption, and competitive pressures in the battery sector. The company's $552 million cash position provides runway but requires successful commercialization to justify valuation.
Tenet Healthcare (THC) trades at $259.83, up 0.53% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026), 82.83% gross margins, and 53.31% ROE. Recent news highlights strong cash flow supporting capital returns, with Q3 2026 results expected October 29, 2026.
THC presents compelling value with a 10.04 P/E ratio and 81.25% analyst buy ratings. Upside potential to $283.36 consensus target exists, though negative cash flow trends and insider selling warrant monitoring. The stock's premium valuation (P/B 4.49) requires sustained execution amid healthcare sector volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →